Engineers Gate Manager LP Adverum Biotechnologies, Inc. Transaction History

Engineers Gate Manager LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $31,695 - $50,249	-25,769 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $44,838 - $61,845	25,769 New	25,769 $45,000
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $81,984 - $257,664	-24,400 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $87,136 - $135,127	-9,410 Reduced 27.83%	24,400 $241,000
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $378,849 - $549,024	-38,501 Reduced 53.24%	33,810 $367,000

Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $744,803 - $1.56 Million	72,311 New	72,311 $745,000
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $85,504 - $204,074	-16,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $87,508 - $265,363	16,700 New	16,700 $91,000

3.6M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $679M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.